pazopanib pharmascience 400 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - pazopanibklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 400 mg pazopaniba u obliku pazopanibklorida
pazopanib teva 200 mg filmom obložene tablete
teva b.v., swensweg 5, haarlem, nizozemska - pazopanibklorid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 200 mg pazopaniba u obliku pazopanibklorida
pazopanib teva 400 mg filmom obložene tablete
teva b.v., swensweg 5, haarlem, nizozemska - pazopanibklorid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 400 mg pazopaniba u obliku pazopanibklorida
pazopanib zentiva 200 mg filmom obložene tablete
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - pazopanibklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 200 mg pazopaniba u obliku pazopanibklorida
pazopanib zentiva 400 mg filmom obložene tablete
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - pazopanibklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 400 mg pazopaniba u obliku pazopanibklorida
votrient 400 mg/1 tableta film tableta
novartis ba d.o.o. - pazopanib - film tableta - 400 mg/1 tableta - 1 filmom obložena tableta sadrži: 400 mg pazopaniba (u obliku pazopanibhidrohlorida)
votrient 200 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - pazopanib - filmom obložena tableta - 200 mg/1 tableta - 1 filmom obložena tableta sadrži: 200 mg pazopaniba (u obliku pazopanib hidrohlorida)
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
pazopanib pharmascience 200 mg/1 tableta filmom obložena tableta
evropa lijek pharma d.o.o. - pazopanib - filmom obložena tableta - 200 mg/1 tableta - 1 filmom obložena tableta sadrži: 200 mg pazopaniba (što je evivalentno 216,70 mg pazopanib hidrohlorida)
pazopanib pharmascience 200 mg/1 tableta filmom obložena tableta
evropa lijek pharma d.o.o. - pazopanib - filmom obložena tableta - 200 mg/1 tableta - 1 filmom obložena tableta sadrži: 200 mg pazopaniba (što je ekvivalentno 216,70 mg pazopanib hidrohlorida)